
Base content of sequences flanking modified cytidine in RNA editing and DNA mutation targets. (A) Base content of 10 nt upstream and 20 nt downstream from edited cytidine in mouse APOBEC1-mediated C-to-U mRNA editing targets. (B) Base content of 10 nt upstream and 10 nt downstream from mutated cytidine in proposed human APOBEC-mediated DNA mutation targets in patients with breast cancer. (C) Comparison of AU base content (%) of nucleotides flanking modified cytidine in RNA editing targets and DNA mutation targets in mouse and human breast cancer patients, respectively.










